Acute monocytic leukemia

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
Acute monocytic leukemia
Classification and external resources
ICD-10 C93.0
ICD-9 206.0
MeSH D007948

WikiDoc Resources for

Acute monocytic leukemia

Articles

Most recent articles on Acute monocytic leukemia

Most cited articles on Acute monocytic leukemia

Review articles on Acute monocytic leukemia

Articles on Acute monocytic leukemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acute monocytic leukemia

Images of Acute monocytic leukemia

Photos of Acute monocytic leukemia

Podcasts & MP3s on Acute monocytic leukemia

Videos on Acute monocytic leukemia

Evidence Based Medicine

Cochrane Collaboration on Acute monocytic leukemia

Bandolier on Acute monocytic leukemia

TRIP on Acute monocytic leukemia

Clinical Trials

Ongoing Trials on Acute monocytic leukemia at Clinical Trials.gov

Trial results on Acute monocytic leukemia

Clinical Trials on Acute monocytic leukemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acute monocytic leukemia

NICE Guidance on Acute monocytic leukemia

NHS PRODIGY Guidance

FDA on Acute monocytic leukemia

CDC on Acute monocytic leukemia

Books

Books on Acute monocytic leukemia

News

Acute monocytic leukemia in the news

Be alerted to news on Acute monocytic leukemia

News trends on Acute monocytic leukemia

Commentary

Blogs on Acute monocytic leukemia

Definitions

Definitions of Acute monocytic leukemia

Patient Resources / Community

Patient resources on Acute monocytic leukemia

Discussion groups on Acute monocytic leukemia

Patient Handouts on Acute monocytic leukemia

Directions to Hospitals Treating Acute monocytic leukemia

Risk calculators and risk factors for Acute monocytic leukemia

Healthcare Provider Resources

Symptoms of Acute monocytic leukemia

Causes & Risk Factors for Acute monocytic leukemia

Diagnostic studies for Acute monocytic leukemia

Treatment of Acute monocytic leukemia

Continuing Medical Education (CME)

CME Programs on Acute monocytic leukemia

International

Acute monocytic leukemia en Espanol

Acute monocytic leukemia en Francais

Businness

Acute monocytic leukemia in the Marketplace

Patents on Acute monocytic leukemia

Experimental / Informatics

List of terms related to Acute monocytic leukemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Acute monocytic leukemia (AMoL, or AML-M5) is considered a type of acute myeloid leukemia. In order to fulfill World Health Organization (WHO) criteria for AML-5, a patient must have greater than 20% blasts in the bone marrow, and of these, greater than 80% must be of the monocytic lineage. A further subclassification (M5a versus M5b) is made depending on whether the monocytic cells are predominantly monoblasts (>80%) (acute monoblastic leukemia) or a mixture of monoblasts and promonocytes (<80% blasts). Monoblasts can be distinguished by having a roughly circular nucleus, delicate lacy chromatin, and abundant, often basophilic cytoplasm. These cells may also have pseudopods. By contrast, promonocytes have a more convoluted nucleus, and their cytoplasm may contain metachromatic granules. Monoblasts are typically MPO negative and promonocytes are MPO variable. Both monoblasts and promonocytes stain positive for non-specific esterase (NSE), however NSE may often be negative.

Immunophenotypically, M5-AML variably express myeloid (CD13, CD33) and monocytic (CD11b, CD11c) markers. Cells may aberrantly express B cels marker CD20 and the NK marker CD56. Monoblasts may be positive for CD34.

M5 is associated with characteristic chromosomal abnormalities, often involving 11q23 or t(9;11)affecting the MLL locus, however the MLL translocation is also found in other AML subtypes. MLL is believed to be prognostically unfavorable in AML-M5 compared to other genetic alterations involving MLL such as t(9;11) The t(8;16) translocation in MLL is associated with hemophagocytosis.

AML-M5 is thought to be associated with exposure to epidophyllotoxins.

AML-M5 is treated with intensive chemotherapy (such as anthracyclines) or with bone marrow transplantation.

External links

WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools